文献速递湿疹皮炎与荨麻疹

产前益生元摄入对高危特应性皮炎婴儿的随机对照试验

Evaluation of antenatal prebiotic intake in infants at risk of atopy: the double-blind PREGRALL randomized clinical trial.
PubMed 文献 · Br J Dermatol · 2026-01-01

PREGRALL多中心双盲随机对照试验纳入376名有特应性疾病史的孕妇,从孕20周至分娩每日补充益生元GOS/菊粉或安慰剂,评估婴儿1岁时特应性皮炎(AD)的发生。结果显示,产前益生元补充未预防AD(ITT OR 1.01,95%CI 0.59-1.74;P=0.97),也未降低疾病严重度,且对过敏原致敏或食物过敏无影响。

要点

  • 产前补充GOS/菊粉益生元未降低婴儿1岁时AD发生风险。
  • 益生元对AD严重度、过敏原致敏及食物过敏均无显著影响。
  • 按母乳喂养状态或分娩方式亚组分析未显示差异。

核心结论

  • 产前母体益生元干预未预防高危婴儿1岁时特应性皮炎。

研究设计与样本

  • 多中心双盲随机对照试验PREGRALL,2018年2月至2023年4月,随访至婴儿1岁。
  • 纳入376名有医生诊断特应性疾病史的孕妇,随机分为益生元GOS/菊粉组(n=188)和安慰剂组(n=188)。
  • 干预从孕20周至分娩每日摄入,主要结局为婴儿1岁时AD发生。

主要发现

  • 意向性分析显示产前益生元未预防AD(OR 1.01,95%CI 0.59-1.74;P=0.97)。
  • 未降低AD严重度,按母乳喂养状态或分娩方式亚组分析无差异。
  • 未发现对过敏原致敏或食物过敏的影响。

关键数值与推荐

  • 主要结局AD发生:OR 1.01,95%CI 0.59-1.74;P=0.97。
  • 亚组分析(母乳喂养状态、分娩方式)未显示差异。

临床怎么用

  • 目前证据不支持对高危孕妇常规补充产前益生元以预防婴儿AD。
  • 未来需探索联合策略预防AD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New primary preventive therapeutic strategies for atopic dermatitis (AD) are needed. Atopic diseases are associated with disrupted gut microbial balance in early life, suggesting that optimizing microflora through intervention could improve health. Prebiotics, which are immunomodulatory sugars, promote gut microbiota diversity. Most clinical trials focus on improving postnatal infant gut colonization, but prenatal life is crucial for establishing tolerance mechanisms. Preclinical studies indicate that maternal intake of galacto-oligosaccharide (GOS)/inulin prebiotics decreases the risk of food allergy in offspring. OBJECTIVES: To determine whether antenatal prebiotic intake prevents AD in children at high risk of atopy. METHODS: The multicentre double-blind randomized PREGRALL clinical trial ran from February 2018 to April 2023 (ClinicalTrials.gov NCT03183440). The follow-up period extended from 20 weeks of amenorrhoea in pregnant women to their infants reaching 1 year of age. Women with a physician-diagnosed history of atopy (asthma, allergic rhinitis, AD or food allergy) were selected for inclusion. The women were randomized to daily prebiotic GOS/inulin (n = 188) or placebo (maltodextrin; n = 188 participants) intake from 20 weeks' gestation until delivery. The first outcome was the occurrence of AD at 1 year in children at risk of the disease. Secondary endpoints included AD severity, quality of life, prebiotic tolerance and the prevalence of other atopic diseases. RESULTS: Of 376 pregnant women included in the trial, prebiotic supplementation did not prevent AD at 1 year (intention-to-treat population odds ratio 1.01, 95% confidence interval 0.59-1.74; P = 0.97) or reduce disease severity in their children. Subgroup analyses by breastfeeding status or delivery mode revealed no differences. No effects on allergen sensitization or food allergies were found. CONCLUSIONS: We found no evidence that maternal intervention with prebiotics protects against AD at 1 year of age in infants at risk of allergic diseases. Atopic dermatitis is a skin condition that causes skin to become red, itchy and inflamed. It is also known as eczema. The condition affects 1 in 5 children worldwide. In France, a team of specialists at a number of university hospitals ran a clinical trial called ‘PREGRALL’. The trial was designed to find out whether giving pregnant women daily prebiotics could lower the chances of eczema in their babies. Between February 2018 and April 2023, 376 pregnant women who had asthma, hay fever, eczema or food allergies were split into two groups. From 20 weeks of pregnancy until they gave birth, women in one group took the prebiotic mix each day. A prebiotic is a type of dietary fibre that feeds good bacteria in the gut. Women in the other group took a harmless dummy drug (‘placebo’) that looked the same as the prebiotic. Neither the doctors nor the mothers knew who was taking the prebiotic or the placebo. When the babies were 1 year old, doctors checked how many had eczema, how severe it was and whether they had any other allergies. We found there was no difference. Babies whose mothers had taken prebiotics when they were pregnant developed eczema just as often and just as severely as those whose mothers had taken the placebo. There were also no changes in food allergies or skin test reactions. Our findings suggest that taking prebiotics during pregnancy alone does not prevent eczema in babies at high risk of the condition. Future studies will need to explore a combination of strategies to find effective ways to prevent eczema before it starts.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Barbarot S, Aubert H, Boivin M, et al. Evaluation of antenatal prebiotic intake in infants at risk of atopy: the double-blind PREGRALL randomized clinical trial. Br J Dermatol. 2026. PMID: 41250898. doi:10.1093/bjd/ljaf414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。